Table 2

Summary of major recent clinical trials in transplant-ineligible patients with newly diagnosed multiple myeloma.

Ref.	Regimen	Cycle of induction	N	CR rate	Median PFS	Median OS
San Miguel et al. [38]	VMP vs.	9	344	30%	19.9 mo	Not reached
San Miguel et al. [38]	MP	9	338	4%	13.1 mo	43.1 mo
Facon et al. [40]	KMP vs.	9	478	25.9%	22.3 mo	NA
Facon et al. [40]	VMP	9	477	23.1%	22.1 mo	NA
Facon et al. [41]	Rd continuous vs.	Continuous	535	0.22	26.0 mo	59.1 mo
	MPT18 vs.	18	541	12%	21.9 mo	49.1 mo
	Rd18	18	547	20%	21.0 mo	62.3 mo
O’Donnell et al. [43]	VRD lite	9	50	44%	35.1 mo	NA
Facon et al. [44]	DRd vs.		368	47.6%	Not reached	NA
Facon et al. [44]	Rd		369	24.9%	31.9 months	NA
Mateos et al. [45]	D-VMP vs.	9	350	42.6%	Not reached	NA
Mateos et al. [45]	VMP	9	356	24.4%	18.1 mo	NA

Abbreviations: CR, complete response; DRd, daratumumab, lenalidomide, and dexamethasone; D-VMP, daratumumab, bortezomib, melphalan, and prednisone; MP, melphalan and prednisone; MPT, melphalan, prednisone, and thalidomide; NA, not available; OS, overall survival; PFS, progression-free survival; Rd, lenalidomide and dexamethasone; Ref, reference; VMP, bortezomib, melphalan, and prednisone; VRD, bortezomib, lenalidomide, and dexamethasone.

Blood Res 2020;55:S37~S42 https://doi.org/10.5045/br.2020.S007